In order to study the consequences of VEGF blockade on 786‐O orthoxenograft tumors, we administered tumor‐bearing mice with anti‐VEGFR2 DC101 (DC) or anti‐human VEGF bevacizumab (Beva) (Fig 1A). This evidence concerns the gene VEGFA and neoplasm.